Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

In a phase 1 trial, Novo Nordisk's experimental obesity drug amycretin led to up to 13% weight loss in just three months.

A new study explores the reasons why tirzepatide, the once-weekly injection used to treat obesity and type 2 diabetes, is ...

If you've recently received a diagnosis of type 2 diabetes, understanding your treatment options is an important first step.

For significant weight loss, Zepbound may be the better option. If you have Type 2 diabetes and are looking for a dual ...

Data from the US FDA's Adverse Event Reporting System on tirzepatide showed adverse events generally consistent with those ...

Weight loss drugs have gained attention as a tool to help combat obesity, but understanding how they work, who they’re for, ...

Natural supplements have “very mild effects” on weight loss based on what Dr. Ali has seen. There is some data to suggest ...

Biomed Industries Unveils novel Quadruple Receptor Agonist for weight loss with Minimal Adverse Effects at the International Obesity conference in Las Vegas Dr. Lloyd L. Tran Biomed Industries, Inc.

Roche is holding out hopes that its injectable obesity prospect could eventually demonstrate 25% weight loss in late-stage ...

Few medications have become as popular and culturally relevant as Ozempic has, but how exactly do it and similar drugs affect ...

Introduction ADVERTISEMENT Peptides have become a focal point in research due to their intricate interactions with metabolic ...